Adjuvant Chemotherapy and Immunotherapy for Colorectal Cancer: Preliminary Communication | Zendy

J Bancewicz | Zendy; K C Caiman | Zendy; Stuart Macpherson | Zendy; C S McArdle | Zendy; J. G. McVie | Zendy; M Soukop | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjuvant Chemotherapy and Immunotherapy for Colorectal Cancer: Preliminary Communication

Author(s) -

J Bancewicz,

K C Caiman,

Stuart Macpherson,

C S McArdle,

J. G. McVie,

M Soukop

Publication year - 1980

Publication title -

journal of the royal society of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.38

H-Index - 81

eISSN - 1758-1095

pISSN - 0141-0768

DOI - 10.1177/014107688007300308

Subject(s) - levamisole , fluorouracil , medicine , colorectal cancer , adjuvant , neutropenia , chemotherapy , oncology , immunotherapy , surgery , adjuvant chemotherapy , oxaliplatin , cancer , breast cancer

Following surgical resection of Dukes’ B or C colorectal cancers 72 patients have been randomly allocated to receive: 5-fluorouracil; or 5-fluorouracil and levamisole; or no treatment. Adjuvant treatment was continued for one year. 66 patients remain evaluable for up to 24 months. Preliminary results show no significant differences in survival or recurrence rates. Two patients receiving 5-fluorouracil and levamisole developed severe, but reversible, neutropenia. Other side effects were uncommon.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research